BIOPHARMA
ByIs Pierre Fabre’s US Cell‑Therapy Comeback Bid a Signal of Regulatory Reset for Rare Diseases?
Pierre Fabre is reviving its US cell‑therapy ambitions, seeking FDA re‑approval for Ebvallo after the agency initially rejected its submission.…
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche has committed $480 million to…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines PepGen’s experimental Duchenne…
Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global pharma sales—yet their…
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…
